Get the Stockscreener App
1.188
1.27%
0.008
After Hours:
1.20
0.012
+1.01%
MAIA Biotechnology Inc stock is traded at $1.188, with a volume of 4.04M.
It is up +1.27% in the last 24 hours and down -3.63% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.18
Open:
$1.3
24h Volume:
4.04M
Relative Volume:
6.87
Market Cap:
$43.99M
Revenue:
-
Net Income/Loss:
$-25.94M
P/E Ratio:
-0.8609
EPS:
-1.38
Net Cash Flow:
$-15.79M
1W Performance:
+20.83%
1M Performance:
-3.63%
6M Performance:
-33.24%
1Y Performance:
-45.93%
1-Day Range:
$1.12
$1.46
1-Week Range:
$0.95
$1.46
52-Week Range:
$0.87
$2.74
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.188 | 43.70M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.60 | 110.02B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.11 | 82.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.56 | 59.61B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
894.90 | 56.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
211.41 | 44.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
MAIA Biotechnology Announces Open Market Purchases by CEO and Directors - GlobeNewswire
Vitoc Vlad buys MAIA biotechnology (MAIA) shares worth $79,848 By Investing.com - Investing.com India
Smith Stan, MAIA Biotechnology director, buys $15,582 in shares By Investing.com - Investing.com India
Smith Stan, MAIA Biotechnology director, buys $15,582 in shares - Investing.com
Luput Cristian, director at Maia Biotechnology, buys $41,845 in shares By Investing.com - Investing.com India
Vitoc Vlad buys MAIA biotechnology (MAIA) shares worth $79,848 - Investing.com
Luput Cristian, director at Maia Biotechnology, buys $41,845 in shares - Investing.com
MAIA Biotechnology Inc Stock Analysis and ForecastMACD Histogram Signals & Affordable Market Trading - earlytimes.in
CEO’s Bold Move: Major Stock Purchase at MAIA Biotechnology! - TipRanks
Luput Cristian, director at Maia Biotechnology, buys $9,785 in shares By Investing.com - Investing.com Australia
Maia Biotech CEO Vitoc Vlad buys $10k in company stock - Investing.com India
Luput Cristian, director at Maia Biotechnology, buys $9,785 in shares - Investing.com
Director Makes Bold Move with Major Stock Purchase in MAIA Biotechnology! - TipRanks
MAIA Biotechnology highlights momentum of ateganosine clinical program - MSN
MAIA Biotechnology CEO presents at Smart Diaspora 2025 - MSN
MAIA Biotechnology Highlights Ateganosine Progress at SITC 2025 - TipRanks
MAIA Biotechnology Highlights Ateganosine Clinical Program at SITC 2025 - TradingView
[8-K] MAIA Biotechnology, Inc. Reports Material Event | MAIA SEC FilingForm 8-K - Stock Titan
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025 - 富途牛牛
MAIA Biotechnology (MAIA) Expands Phase 2 Lung Cancer Trial and Opens Phase 3 Study - Stock Titan
MAIA Biotechnology Expands Phase 2 Study in Romania - TipRanks
MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation - The Manila Times
MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Conference - TradingView
MAIA Biotechnology CEO Presents Telomere Targeting Efficacy - GlobeNewswire
Will MAIA Biotechnology Inc. stock rise with strong economyPortfolio Return Summary & Detailed Earnings Play Alerts - newser.com
MAIA Biotechnology (NYSE American: MAIA) Reports 38% Response in THIO-101 NSCLC Study in Romania - Stock Titan
Can MAIA Biotechnology Inc. stock survive global slowdownJuly 2025 Closing Moves & Consistent Income Trade Ideas - newser.com
Real time breakdown of MAIA Biotechnology Inc. stock performanceQuarterly Portfolio Report & High Accuracy Trade Signal Alerts - newser.com
Will MAIA Biotechnology Inc. stock see PE expansionWeekly Trend Recap & Free Weekly Watchlist of Top Performers - newser.com
What MACD and RSI say about MAIA Biotechnology Inc.July 2025 Outlook & Safe Capital Preservation Plans - newser.com
Is MAIA Biotechnology Inc. stock positioned for digital transformation2025 Major Catalysts & Smart Money Movement Alerts - newser.com
Will MAIA Biotechnology Inc. stock recover after recent dropWeekly Earnings Recap & Weekly Return Optimization Alerts - newser.com
Why global investors buy MAIA Biotechnology Inc. stockMarket Trend Review & Free Technical Confirmation Trade Alerts - newser.com
How to use a screener to detect MAIA Biotechnology Inc. breakoutsTrade Performance Summary & Verified Momentum Stock Alerts - newser.com
What momentum shifts mean for MAIA Biotechnology Inc.July 2025 Summary & Weekly Stock Performance Updates - newser.com
Historical volatility pattern of MAIA Biotechnology Inc. visualizedJuly 2025 Intraday Action & Free Weekly Watchlist of Top Performers - newser.com
Is MAIA Biotechnology Inc. stock bottoming outPortfolio Profit Report & Reliable Price Breakout Alerts - newser.com
Applying sector rotation models to MAIA Biotechnology Inc.Market Activity Report & Free Fast Gain Swing Trade Alerts - newser.com
Is MAIA Biotechnology Inc. stock among top earnings plays2025 Trade Ideas & AI Powered Market Entry Strategies - newser.com
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
1.70%
Cap:
|
Volume (24h):